Drug approvals build pipeline, but interim loss and weak revenue weigh
New drug approvals expand pharmaceutical pipeline Jianfeng's drug subsidiary won Chinese approval for two new products: injectable tedizolid phosphate (a hospital antibiotic) and compound tropicamide eye drops, which are already on the national reimbursement and essential drug lists. Each approval adds a future sales stream, supporting the shares.
Two fresh regulatory approvals are the clearest new positive for the company's pharma business.
Methyldopa API cleared for China and Europe The subsidiary's methyldopa ingredient was approved for domestic sale, then won a European CEP certificate letting it enter the EU and other markets that accept it. This opens export revenue for a mature blood-pressure drug, a modest but real growth driver.
The domestic and European methyldopa approvals are new and directly widen the company's market.
Products proposed for national drug procurement Jianfeng was among Shanghai-listed drugmakers saying its products were proposed for selection in China's 12th national centralized procurement round. Winning government bulk-buying contracts usually means large guaranteed volumes, though at lower prices, so it lifts sales expectations.
Selection in national procurement is a new, concrete demand signal for the company's drugs.
Interim report swings to a loss as revenue falls First-half revenue dropped 10.33% to 1.165 billion yuan and the company swung from profit to a net loss of 8.95 million yuan. This is the main counterweight: the core business is shrinking and unprofitable, which pressures the share price despite the drug approvals.
The loss is the biggest new negative and offsets the positive pipeline news.